Finally the stock market and many individual names have started to move enough to create profits in a very short time frame.

The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?

360 Biotech's contrarian thesis on the weight loss drugs developer published in 2013 was unwelcoming but turned out valid. Stock promoters who were overly exuberant on Arena, Orexigen, and/or VIVUS mislead investors.

The FDA issued a delay for Orexigen's (OREX) obesity drug Contrave, The stock has now fallen by more than 15% in pre-market trading, creating an investment opportunity for patient investors.

The average small cap score is 47.75 this week, below the four week moving average score of 51.67. The average small cap stock is trading 23.9% below its 52 week high, 0.36% above its 200 dma, and has 7.05 days to cover short.

There's a war on folks, and it's not going on in the Ukraine or Afghanistan – it's a war right here in the USA between the top 1% and everyone else.